Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))
| dc.contributor.author | Roldan Menco, Consuelo | |
| dc.contributor.author | Díaz-Pérez, Anderson | |
| dc.contributor.author | Barrios Puerta, Zoraida | |
| dc.date.accessioned | 2019-05-15T20:00:01Z | |
| dc.date.available | 2019-05-15T20:00:01Z | |
| dc.date.issued | 2019 | |
| dc.description.abstract | Introduction: The Metabolic Syndrome is a set of diverse clinical situations such as diabetes mellitus, hypertension and dyslipidemia. Patients with mental illnesses such as schizophrenia or bipolar disorder have a higher mortality than the general population attributable in 60% to somatic diseases and metabolic syndrome, where second generation antipsychotics increase the risk of weight gain and insulin resistance. Objectives. Correlate the treatment with second generation antipsychotics (SGAs) as a possible predictor for Metabolic Syndrome according to the NCEP ATP III (a) classification. Methods: Descriptive, cross-sectional correlational study. The sample was of 92 patients, applying an open and convenience sampling due to the mental state of the patients in order to determine their degree of acceptance to the study (Informed Assent) and consent to the legal guardian as the main inclusion criterion. For the analysis, the following variables were considered: blood pressure, weight, height, abdominal circumference, serum levels of triglycerides, glucose and high density lipoproteins. The SPSS 20.0 ® program was used logistic regression analysis with a p-value <0.05 and a confidence level of 95%. Results: SGAs most used was clozapine (54.3%). The correlation analysis showed that sociodemographic aspects such as personal history, habits, physical activity and paraclinical and anthropometric records correlated with the possible diagnosis of metabolic syndrome (p <0.05), but not with SGAs (p> 0.05). ). Conclusion: No correlation was found between the presence of the metabolic syndrome and the type of antipsychotic treatment. | eng |
| dc.identifier.issn | 19169736 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12442/3021 | |
| dc.language.iso | eng | eng |
| dc.publisher | Canadian Center of Science and Education | eng |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Global Journal of Health Sciencia | eng |
| dc.source | Vol. 11, No. 1 (2019) | eng |
| dc.source.uri | https://doi.org/10.5539/gjhs.v11n1p28 | eng |
| dc.subject | Second generation antipsychotics | eng |
| dc.subject | Schizophrenic patients | eng |
| dc.subject | Bipolar disorder | eng |
| dc.subject | Metabolic syndrome | eng |
| dc.title | Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a)) | eng |
| dc.type | article | eng |
| dcterms.references | Aguilar, E., Coronas, R., & Caixàs, A. (2012). Síndrome metabólico en pacientes esquizofrénicos con tratamiento antipsicótico. Medicina clínica, 139(12), 542-546. https://doi.org/10.1016/j.medcli.2012.05.028 | spa |
| dcterms.references | Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006). Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabetic medicine, 23(5), 469-480. https://doi.org/10.1111/j.1464-5491.2006.01858.x | eng |
| dcterms.references | Atun, R., De Andrade, L. O. M., Almeida, G., Cotlear, D., Dmytraczenko, T., Frenz, P., … Muntaner, C. (2015). Health-system reform and universal health coverage in Latin America. The Lancet, 385(9974), 1230-1247. https://doi.org/10.1016/S0140-6736(14)61646-9 | eng |
| dcterms.references | Choo CC, Chew PKH, Ho CS, Ho RC. Prediction of Quality of Life in Asian Patients with Schizophrenia: A Cross-sectional Pilot Study. Front Psychiatry, 5(8), 198. https://doi.org/10.3389/fpsyt.2017.00198 | eng |
| dcterms.references | Correll, C. U., Detraux, J., Lepeleire, J., & De Hert, M. (2015). Efectos de antipsicóticos, antidepresivos y estabilizadores del estado de ánimo sobre el riesgo de enfermedades físicas en personas con esquizofrenia, depresión y trastorno bipolar. WPA, 14, 119-136. | spa |
| dcterms.references | Cortés Morales, B. (2011). Síndrome metabólico y antipsicóticos de segunda generación. Revista de la Asociación Espa-ola de Neuropsiquiatría, 31(2), 303-320. https://doi.org/10.4321/S0211-57352011000200009 | spa |
| dcterms.references | De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., & Möller, H.-J. (2009). Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave: Declaración de la posición de la Sociedad Psiquiátrica Europea (EPA), respaldada por la Asociación Europea para el Estudio de la Diabetes (EASD) y la Sociedad Europea de Cardiología (ESC). Revista de Psiquiatría y Salud Mental, 2(1), 49-59. https://doi.org/10.1016/S1888-9891(09)70714-1 | spa |
| dcterms.references | Estévez, M. J. V., Domínguez, M. F., Corti-as, M. J. L., Seoane, M. N., Sánchez, E. P., & Quintas, C. M. G. (2013). Prevalencia del síndrome metabólico en esquizofrenia y trastorno bipolar:?` sería útil un protocolo de control cardiovascular? Cadernos de atención primaria, 19(4), 215–222. | spa |
| dcterms.references | Expert Panel on Detection, E. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama, 285(19), 2486. https://doi.org/10.1001/jama.285.19.2486 | eng |
| dcterms.references | Firmann, M., Mayor, V., Vidal, P. M., Bochud, M., Pécoud, A., Hayoz, D., … Yuan, X. (2008). The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC cardiovascular disorders, 8(1), 6. https://doi.org/10.1186/1471-2261-8-6 | eng |
| dcterms.references | García-García, E., la Llata-Romero, D., Kaufer-Horwitz, M., Tusié-Luna, M. T., Calzada-León, R., Vázquez-Velázquez, V., … Velázquez-Fernández, D. (2008). La obesidad y el síndrome metabólico como problema de salud pública. Una reflexión. Acta pediátrica de México, 29(4), 227-245. | spa |
| dcterms.references | Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., … Program, C. C. of the N. C. E. (2004). Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Journal of the American College of Cardiology, 44(3), 720-732. https://doi.org/10.1016/j.jacc.2004.07.001 | eng |
| dcterms.references | Heng, D., Ma, S., Lee, J. J., Tai, B. C., Mak, K. H., Hughes, K., … Tai, E. S. (2006). Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis, 186(2), 367-373. https://doi.org/10.1016/j.atherosclerosis.2005.07.020 | eng |
| dcterms.references | Ho, C. S., Zhang, M. W., Mak, A., Ho, R. C. (2014). Metabolic syndrome in psychiatry: advances in understanding and management. Advances in Psychiatric Treatment, 20, 101-112. https://doi.org/10.1192/apt.bp.113.011619 | eng |
| dcterms.references | Jaramillo, C. L., Mejía, A. C., Velásquez, A. H., Palacio, T. F. R., & Zuluaga, J. O. (2013). Síndrome metabólico y trastorno afectivo bipolar: una revisión de la literatura. Revista Colombiana de Psiquiatría, 42(3), 283-291. https://doi.org/10.1016/S0034-7450(13)70021-0 | spa |
| dcterms.references | Kavey, R.-E. W., Daniels, S. R., Lauer, R. M., Atkins, D. L., Hayman, L. L., & Taubert, K. (2003). American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation, 107(11), 1562–1566. https://doi.org/10.1161/01.CIR.0000061521.15730.6E | eng |
| dcterms.references | Lakka, H.-M., Laaksonen, D. E., Lakka, T. A., Niskanen, L. K., Kumpusalo, E., Tuomilehto, J., & Salonen, J. T. (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama, 288(21), 2709-2716. https://doi.org/10.1001/jama.288.21.2709 | eng |
| dcterms.references | Levav, I., Lima, B. R., Somoza Lennon, M., Kramer, M., & Salvatierra-González, R. (1989). Salud mental para todos en America Latina y el Caribe: bases epidemiologicas para la accion. | spa |
| dcterms.references | Martinez, M. I. V., León, F., Torres, R., & Crossley, N. A. (2017). Antipsicóticos de primera y segunda generación en esquizofrenia: eficacia, efectividad y efecto de la dosis utilizada. ARS MEDICA Revista de Ciencias Médicas, 42(1), 41-48. https://doi.org/10.11565/arsmed.v42i1.452 | spa |
| dcterms.references | McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., … Lieberman, J. A. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia research, 80(1), 19-32. https://doi.org/10.1016/j.schres.2005.07.014 | eng |
| dcterms.references | Menco, C. R., & Pérez, A. D. (2011). Otros factores asociados con síndrome metabólico? Ciencia y Salud Virtual, 3(1), 135-143. https://doi.org/10.22519/21455333.300 | spa |
| dcterms.references | Moreno, T. S.-A., González, R. T., Fleta, J. L. H., & Pérez, P. L. (2006). Alta prevalencia de síndrome metabólico en pacientes esquizofrénicos: una revisión de la literatura. Psiquiatría Biológica, 13(4), 127–135. https://doi.org/10.1016/S1134-5934(06)75353-2 | spa |
| dcterms.references | Mu-oz, P., & Gallardo, R. (2004). Trastornos metabólicos en pacientes esquizofrénicos tratados con Clozapina. | spa |
| dcterms.references | Mu-oz-Calero Franco, P., Sánchez Sánchez, B., Rodríguez Criado, N., Pinilla Santos, B., Bravo Herrero, S., Fourcade, C., … Martín Aragón, R. (2015). Síndrome metabólico y riesgo cardiovascular en pacientes con diagnóstico de esquizofrenia, trastorno esquizoafectivo y trastorno bipolar. Nutrición Hospitalaria, 32(6), 2715–2717. | spa |
| dcterms.references | Newcomer, J. W. (2007a). Antipsychotic medications: metabolic and cardiovascular risk. The Journal of clinical psychiatry. | eng |
| dcterms.references | Newcomer, J. W. (2007b). Metabolic syndrome and mental illness. The American journal of managed care, 13(7 Suppl), S170-7. | eng |
| dcterms.references | Ortiz Lobo, A., & Ibá-ez Rojo, V. (2011). Iatrogenia y prevención cuaternaria en salud mental. Revista Espa-ola de Salud Pública, 85(6), 513-525. https://doi.org/10.1590/S1135-57272011000600002 | spa |
| dcterms.references | Park, B., & Lee, Y.-J. (2018). Metabolic syndrome and its components as risk factors for prolonged corrected QT interval in apparently healthy Korean men and women. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2018.07.004 | eng |
| dcterms.references | Pato, C. M. F., Rodríguez, V. M., & Valverde, J. I. F. (2017). Síndrome metabólico y antipsicóticos atípicos. Posibilidad de predicción y control. Revista de Psiquiatría y Salud Mental, 10(1), 38-44. https://doi.org/10.1016/j.rpsm.2016.09.003 | spa |
| dcterms.references | Pineda, C. A. (2008). Síndrome metabólico: definición, historia, criterios. Colombia médica, 39(1). | spa |
| dcterms.references | Rojo, L., Mesa, F., & Martínez-Ortega, J. M. (2014). Prevalencia del síndrome metabólico en pacientes espa-oles con esquizofrenia y sobrepeso. El estudio CRESSOB. Actas Esp Psiquiatr, 42(1), 9-17. | spa |
| dcterms.references | Stergiou, G. S., Asmar, R., Myers, M., Palatini, P., Parati, G., Shennan, A., … Monitoring, E. S. of H. W. G. on B. P. (2018). Improving the accuracy of blood pressure measurement: the influence of the European Society of Hypertension International Protocol (ESH-IP) for the validation of blood pressure measuring devices and future perspectives. LWW. https://doi.org/10.1097/HJH.0000000000001635 | eng |
| dcterms.references | Thomas, G. N., Ho, S.-Y., Janus, E. D., Lam, K. S., Hedley, A. J., Lam, T. H., & Committee, H. K. C. R. F. P. S. S. (2005). The US national cholesterol education programme adult treatment panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes research and clinical practice, 67(3), 251-257. https://doi.org/10.1016/j.diabres.2004.07.022 | eng |
| dcterms.references | Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., … Correll, C. U. (2015). Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry, 14(3), 339-347. https://doi.org/10.1002/wps.20252 | eng |
| dcterms.references | Williams, B., Poulter, N. R., Brown, M. J., Davis, M., McInnes, G. T., Potter, J. F., … Thom, S. M. (2004). Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. Journal of human hypertension, 18(3), 139. https://doi.org/10.1038/sj.jhh.1001683 | eng |